Z大限度發(fā)揮血清β淀粉酶檢測(cè)在老年癡呆癥的診斷中的作用

zui大限度發(fā)揮血清β淀粉酶檢測(cè)在老年癡呆癥的診斷中的作用

Neuromolecular Med. 2008 ; 10（3）: 195–207. doi:10.1007/s12017-008-8035-0.

Maximizing the Potential of Plasma Amyloid-beta as a Diagnostic
Biomarker for Alzheimer’s Disease
Esther S. Oh, M.D.a,b*, Juan C. Troncoso, M.D.b,c, and Stina M. Fangmark Tucker, Ph.D.
aDepartment of Medicine, The Johns Hopkins University School of Medicine, 558 Ross Research Building,
720 Rutland Ave., Baltimore, MD
bDepartment of Pathology, The Johns Hopkins University School of Medicine, 558 Ross Research Building,
720 Rutland Ave., Baltimore, MD
cDepartment of Neurology, The Johns Hopkins University School of Medicine, 558 Ross Research Building,
720 Rutland Ave., Baltimore, MD
Abstract
Amyloid plaques are composed primarily of amyloid-beta （Aβ） peptides derived from proteolytic
cleavage of amyloid precursor protein （APP）, and are considered to play a pivotal role in Alzheimer's
disease （AD） pathogenesis. Presently, AD is diagnosed after the onset of clinical manifestations.
With the arrival of novel therapeutic agents for treatment of AD, there is an urgent need for
biomarkers to detect early stages of AD. Measurement of plasma Aβ has been suggested as an
inexpensive and non-invasive tool to diagnose AD and to monitor Aβ modifying therapies. However,
the majority of cross-sectional studies on plasma Aβlevels in humans have not shown differences
between individuals with AD compared to controls. Similarly, cross-sectional studies of mouse
plasma Aβ have yielded inconsistent trends in different mouse models. However, longitudinal studies
appear to be more promising in humans. Recently, efforts to modify plasma Aβ levels using
modulators have shown some promise. In this review, we will summarize the present data on plasma
Aβ in humans and mouse models of AD. We will discuss the potential of modulators of Aβ levels
in plasma including antibodies and insulin, and the challenges associated with measuring plasma
Aβ. Modulators of plasma Aβ may provide an important tool to optimize plasma Aβ levels, and may
improve the diagnostic potential of this approach.